Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022GlobeNewsWire • 10/24/22
Vyant Bio to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 08/31/22
Vyant Bio posts Q2 results, set to advance VYNT-0126 to treat Rett Syndrome into clinical trials early next yearProactive Investors • 08/23/22
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/23/22
Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business HighlightsGlobeNewsWire • 08/22/22
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022GlobeNewsWire • 08/19/22
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022GlobeNewsWire • 08/11/22
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations ServicesGlobeNewsWire • 06/01/22
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/17/22
Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseasesProactive Investors • 05/16/22
Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business HighlightsGlobeNewsWire • 05/16/22
Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022GlobeNewsWire • 05/10/22
Vyant Bio Announces Participation in BioNJ's 12th Annual BioPartnering ConferenceGlobeNewsWire • 05/05/22
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?InvestorPlace • 03/30/22
Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/30/22
Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discoveryProactive Investors • 03/30/22
Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business HighlightsGlobeNewsWire • 03/30/22
Vyant Bio enters collaboration with OrganoTherapeutics to find treatments for Parkinson's DiseaseProactive Investors • 03/30/22
Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson's DiseaseGlobeNewsWire • 03/29/22
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021GlobeNewsWire • 03/28/22
Vyant Bio says it is ‘well-positioned' to discover novel therapeutics to treat neurological diseasesProactive Investors • 03/01/22